Lupin, Medicis Reach Deal Over Generic Solodyn

Law360, New York (July 25, 2011, 6:18 PM EDT) -- Lupin Ltd. said Monday it had reached a deal with Medicis Pharmaceutical Corp. to make a generic version of the acne drug Solodyn and to start a development collaboration worth an initial $20 million, resolving patent litigation in Maryland federal court.

The agreement allows Mumbai-based Lupin to sell a generic version of Solodyn in three different doses as early as November, according to the company. In a separate agreement, Lupin said it would join forces with Medicis to use its proprietary formulation technology to develop new...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.